Cytokinetics heart drug scores in closely watched trial
Source ↗
👁 0
💬 0
Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.
Comments (0)